Milos Brodak

Milos Brodak

Auto-generated profile, based on publicly available information

Milos Brodak

Department of Urology, Charles University Hospital, Hradec Kralove, Czech Republic

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2010 in Strahlentherapie und Onkologie
Verified
Journal Article
Closed access
PDF file
MDMartin Doležel
Martin Doležel
KOKarel Odrazka
Karel Odrazka
MVMiloslava Vaculikova
Miloslava Vaculikova
JVJaroslav Vanasek
Jaroslav Vanasek
JSJana Sefrova
Jana Sefrova
IHIgor Hartmann
Igor Hartmann

1 March 2011 in Brachytherapy
Verified
Journal Article
Closed access
JPJiří Petera
Jiří Petera
ISIgor Sirak
Igor Sirak
LKLinda Kašaová
Linda Kašaová
ZMZuzana Mačingová
Zuzana Mačingová
PPPetr Paluska
Petr Paluska
MVMilan Vošmik
Milan Vošmik

29 December 2009 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
KOK Odrazka
K Odrazka
MDM Dolezel
M Dolezel
JVJ Vanasek
J Vanasek
MVM Vaculikova
M Vaculikova
MZM Zouhar
M Zouhar
PPP Prosvic
P Prosvic

26 April 2017 in BMC Urology
Verified
Journal Article
Open access
PDF file
MFMiroslav Fajfr
Miroslav Fajfr
MLMiroslav Louda
Miroslav Louda
PPPavla Paterova
Pavla Paterova
LRLenka Ryšková
Lenka Ryšková
JPJaroslav Pacovský
Jaroslav Pacovský
MBMiloš Broďák
Miloš Broďák
Against a background of rapid increase of β-lactamase-producing or multi-resistant pathogenic bacteria and the resulting lack of effective antibiotic treatment, some older antibiotics have been tested for new therapeutic uses. One of these is fosfomycin, to which according to studies these resistant bacteria are very sensitive. Our study was designed because there is no data on the fosfomycin susceptibility rate in the Czech Republic. In this study from January 2013 to June 2014 3295 unique isolates of Gram-negative bacteria which had caused urinary tract infections were examined. The antibiotic susceptibility was measured by disk diffusion test. Both EUCAST and CLSI guidelines criteria (for fosfomycin only) were used for the antibiotic susceptibility evaluation. The most frequently tested bacterial isolates were Escherichia coli (51.3%, n = 1703), Klebsiella pneumoniae (19.4%, n = 643) and Proteus spp. (11.8%, n = 392). Among all isolates 29.0% (n = 963) were resistant to fluoroquinolones, 11.3% (n = 374) produced extended spectrum β-lactamase and 4.2% (n = 141) produced AmpC β-lactamase. The overall in vitro susceptibility was significantly higher for fosfomycin compared to the other tested per-oral antibiotics (nitrofurantoin, ampicillin, co-trimoxazole, ciprofloxacin and cefuroxime) against all tested Gram-negative rod isolates (excluding Morganella morgani and Acinetobacter spp. isolates). Fosfomycin also remained highly active against those isolates with extended spectrum β-lactamase (ESBL) production (95.8% in Escherichia coli isolates and 85.3% in Klebsiella pneumoniae isolates), unlike other tested per-oral antibiotics, which showed significant (p < 0.0001) susceptibility decrease. We have confirmed in the Czech Republic the very high susceptibility to fosfomycin trometamol of urinary tract infection pathogens, particularly Gram-negative rods including those producing β-lactamase.

1 January 2010 in European Urology
Verified
Journal Article
Closed access
FZFrantišek Zát’ura
František Zát’ura
JVJaroslav Všetiča
Jaroslav Všetiča
MAMontserrat Abadías
Montserrat Abadías
IPIvan Pavlík
Ivan Pavlík
PSPeter Schraml
Peter Schraml
MSMariá Sust
Mariá Sust

22 August 2010 in International Journal of Urology
Verified
Journal Article
Closed access
PDF file
KOKarel Odrazka
Karel Odrazka
MDMartin Dolezel
Martin Dolezel
JVJaroslav Vanasek
Jaroslav Vanasek
MVMiloslava Vaculikova
Miloslava Vaculikova
MZMilan Zouhar
Milan Zouhar
PHPetr Hoffmann
Petr Hoffmann